article thumbnail

Do patients care about accelerated approval drugs?

World of DTC Marketing

85% of accelerated approvals from 2010 to 2020 were for oncology indications. Patients trust their doctors, so the accelerated approval process must be modified to increase their trust with physicians and explain to patients precisely what accelerated drug approval means. Of course not.

Patients 200
article thumbnail

American health is in for a “world of hurt”

World of DTC Marketing

Cardiovascular disease deaths in the US have increased by nearly 17% since 2010, and are among the reasons that life expectancy in the U.S. has also seen reversals in health improvements since 2010, partly due to increasing rates of obesity, high blood pressure, and high blood sugar. . is lower than in other high-income countries.

Insurance 190
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Monday Healthcare Headlines

World of DTC Marketing

According to an AARP study, in 2010 there were 7 potential caregivers for every person over 80. The rest were additional approvals of an existing drug or first approvals of a “me-too” drug that enters an existing class of treatment. Care Giving Crisis.

article thumbnail

Susan Torroella, 2020-2021 HBA STAR

Pharma Marketing Network

The 2020-2021 HBA STAR is Susan Torroella, President and CEO of ArmadaHealth, the leader in physician recommendation intelligence provided to employers through its QualityCare Connect? Having also served on HBA’s Advisory Board, Council of Chapter Presidents and as a mentor to the European Chapter and numerous U.S.

article thumbnail

How AI Can Help Medical Science Liaisons Juggle Their Ever-Growing Responsibilities

PM360

1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. In fact, the pharmaceutical industry’s development pipeline has reached an all-time high of 20,109 products under active development at the end of January 2022, an increase of 500 from 2021.

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. The US biosimilars market is notably underdeveloped and biosimilar entry in the US has been difficult, consistently lagging behind Europe.

article thumbnail

Fixed-dose combination: Considerations for design, formulation, manufacturing and analysis

Pharmaceutical Technology

Between 2010 and the end of 2015, of the 655 New Drug Applications (NDAs) approved by the FDA, 63 were for FDCs. Among the numerous advantages FDCs offer patients, physicians, and pharmaceutical companies, several are particularly noteworthy. With an FDC product, physician offices also have fewer prescriptions and renewals to process.